NRG-GI011, A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

Sponsor:

NRG

Sponsor Study ID:

NRG-GI011

CTO #:

104238

NCT Number:

NCT06958328

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Pancreas

Study Objectives:

To evaluate whether dose-escalated RT improves 3-year overall survival (OS) compared to standard treatments without dose-escalated RT, in locally advanced pancreatic cancer patients without radiographic progression and with biochemical response after an initial interval of chemotherapy.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)